눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.
P321
(…) 처치를 하시오.
P330
입을 씻어내시오.
P332+P313
피부 자극이 생기면 의학적인 조치· 조언을 구하시오.
P362
오염된 의복을 벗고 세척 후에 재사용하기
P501
...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
2
0
Luliconazole C화학적 특성, 용도, 생산
개요
Luliconazole is a member of the imidazole class of antifungal agents, with specific
utility as a dermatological antimycotic drug. It was launched in Japan as a
topical agent for the treatment of athlete’s foot. Luliconazole is an optically active
drug with (R)-configuration at its chiral center. It is structurally related to lanoconazole,
which has been marketed as a racemic mixture since 1994. As with other
azole antifungal drugs, the mechanism of action of luliconazole is the inhibition of
sterol 14-a-demethylase, and subsequently, inhibition of ergosterol biosynthesis. The in
vivo activity of luliconazole against dermatophytes has been evaluated in the guinea
pig model of tinea pedis. In this study, a 1% topical solution of luliconazole, administered
once daily for seven days, achieved complete mycologic cure. Additionally,
there were no occurrences of relapse for up to 16 weeks after the treatment. No
data is currently available on the clinical efficacy of luliconazole. The chemical synthesis
of luliconazole involves the condensation of 1-(cyanomethyl)imidazole with
carbon disulfide to produce a dithioate intermediate, and subsequent alkylation with
either the mesylate derivative of (S′)-1-(2,4-dichlorophenyl)-2-bromoethanol or the
bis-mesylate derivative of (S′)-1-(2,4-dichlorophenyl)ethane-1,2-diol.
.
용도
Luliconazole is an azole antifungal drug. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Mode of action
The mechanism of action of luliconazole is as a Cytochrome P450 2C19 Inhibitor.
